Mouse monoclonal antibody against human CD61 (integrin ß3; platelet GPIIIa / vitronectin-receptor ß3 chain), clone CRC54, 0.2 mg. Reacts with the platelet glycoprotein GPIIIa — the common ß3 subunit shared by the GPIIb/IIIa (aIIbß3) fibrinogen receptor and the avß3 vitronectin receptor. Unlike the complex-specific cat. 751 (clone CRC64), CRC54 recognises the ß3 chain itself and therefore works under both reduced and non-reduced conditions. For platelet and megakaryocyte identification, FACS, immunofluorescence, IHC and immunoblotting.
SPECIFICATIONS
Catalogue number: 879 | Host: Mouse | Target: Human
Target antigen: CD61 / integrin ß3 (platelet GPIIIa; vitronectin-receptor ß3 chain)
Gene: ITGB3 (17q21.32) | UniProt: P05106
Clonality: Monoclonal | Clone: CRC54 | Conjugate: Unconjugated
Specificity: Reacts with the human platelet GPIIIa / ß3 chain — the subunit common to aIIbß3 and avß3.
Purification: Ammonium sulphate precipitation and DEAE-cellulose chromatography.
Format: Lyophilised (mannitol, dextran, salts) | Package size: 0.2 mg (reconstitute in 1 mL sterile water)
STORAGE / RECONSTITUTION
Reconstitute with 1 mL sterile pure water. Ships at ambient temperature. Store lyophilised antibody 2 years at -20 °C or lower; store reconstituted antibody at +4 °C up to 4 weeks, or aliquot and freeze at -20 °C. Avoid repeated freeze-thaw.
APPLICATIONS
- Flow cytometry (FACS) — determination of thrombocytes in blood and platelet identification.
- Immunofluorescence and IHC (frozen sections) — identification of megakaryocytes and blasts in tissue.
- Immunoblotting — works under both reduced and non-reduced conditions.
- Immunoassay — detection of conformational changes of GPIIb/IIIa on activated platelets.
APPLICATION HIGHLIGHTS — HIGH-VALUE RESEARCH NICHES
- Platelet and megakaryocyte lineage identification — CD61 as the definitive marker.
- Glanzmann thrombasthenia research — ß3 (GPIIIa) deficiency.
- Platelet-activation studies — GPIIb/IIIa conformational change.
- avß3 vitronectin-receptor biology — angiogenesis, adhesion and tumour invasion.
